Immunosuppression and Protective Immunity in Tumor Microenvironment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 1519

Special Issue Editors


E-Mail Website
Guest Editor
Brown Center for Immunotherapy, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA
Interests: immune suppressive; tumor microenvironment; glioblastoma; GI cancers; cancer metastasis

E-Mail Website
Guest Editor
Brown Center for Immunotherapy, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA
Interests: epigenetics; immunotherapy and immunomodulation; IBD; IBD-associated colorectal cancer; sporadic colorectal cancer

Special Issue Information

Dear Colleagues,

The tumor microenvironment (TME) is a dynamic ecosystem that includes not only cancer cells but also immune cells, stromal cells, as well as various tissue-resident cell types. Tumor microenvironments play crucial roles in tumor development, progression, and responses to treatment, including immunotherapy. In tumors, various mechanisms are involved in immunosuppressive microenvironments, including immunometabolism, immune checkpoint molecules, and immunosuppressive immune cells. On the other hand, the immune system comprises multiple factors able to provide comprehensive protective immune responses against tumors. The interplay between immunosuppression and protective immunity in the tumor microenvironment is critical for tumor development, and strategies aiming to overcome immunosuppression and enhance protective immune responses have been intensively developed recent years.  

We are pleased to invite you to submit your research paper to Cancers. This Special Issue aims to understand the role of immunoregulation in the TME as well as the genetic and epigenetic mechanisms in the TME. This Special Issue also aims to discuss updated knowledge and research on immune checkpoints, biomarkers, and therapy strategies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Mechanisms of immunosuppression in the tumor microenvironment;

- Immune checkpoints and their role in tumor immunity;

- Immunotherapeutic strategies for overcoming immunotherapy resistance;

- Cellular and molecular interactions in the tumor microenvironment;

- Biomarkers for predicting immunosuppression and therapeutic response;

- Immunometabolism in the context of tumor immunity.

Prof. Dr. Yaoqi A. Wang
Dr. Fei Gao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune suppression
  • tumor microenvironment
  • protective immunity
  • immune checkpoints
  • immunotherapy
  • cellular interactions
  • molecular interactions
  • biomarkers
  • immunometabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2328 KiB  
Article
Modulating Tumor Immunity by Targeting Tumor Fibrotic Stroma and Angiogenic Vessels for Lung Cancer Treatment
by Yi Yuan, Falguni Mishra, Bin Li, Guangda Peng, Payton Chan, Jenny Yang and Zhiren Liu
Cancers 2024, 16(13), 2483; https://doi.org/10.3390/cancers16132483 - 8 Jul 2024
Viewed by 1251
Abstract
Fibrotic stroma and angiogenic tumor vessels play an important role in modulating tumor immunity. We previously reported a rationally designed protein (ProAgio) that targets integrin αvβ3 at a novel site. ProAgio induces the apoptosis of cells that express high levels [...] Read more.
Fibrotic stroma and angiogenic tumor vessels play an important role in modulating tumor immunity. We previously reported a rationally designed protein (ProAgio) that targets integrin αvβ3 at a novel site. ProAgio induces the apoptosis of cells that express high levels of the integrin. Both activated cancer-associated fibroblasts (CAFs) and angiogenic endothelial cells (aECs) in tumors express high levels of integrin αvβ3. ProAgio simultaneously and specifically induces apoptosis in CAFs and aECs in tumors. We provide evidence here that the depletion of CAFs and the elimination of leaky tumor angiogenic vessels by ProAgio alter tumor immunity. ProAgio reduces CD4+ Treg and Myeloid-derived suppressor cells (MDSCs), increases CD8+ T-cells, and increases the M1/M2 macrophage ratio in the tumor. The depletion of dense fibrotic stroma (CAFs) by ProAgio decreases the Programmed Death Ligand 1 (PDL-1) levels in the stroma areas surrounding the tumors, and thus strongly increases the delivery of anti-PDL-1 antibody to the target cancer cells. The impact of ProAgio on tumor immunity provides strong synergistical effects of checkpoint inhibitors on lung cancer treatment. Full article
(This article belongs to the Special Issue Immunosuppression and Protective Immunity in Tumor Microenvironment)
Show Figures

Figure 1

Back to TopTop